Record Display for the EPA National Library Catalog


Main Title Pharmacokinetics in Risk Assessment: Drinking Water and Health. Volume 8.
CORP Author National Research Council, Washington, DC.;Environmental Protection Agency, Washington, DC.;National Institutes of Health, Bethesda, MD.
Publisher 1987
Year Published 1987
Report Number ISBN-0-309-03775-1; EPA-68-01-3169 ;EPA-68-02-3809;
Stock Number PB89-203319
Additional Subjects Potable water ; Water treatment ; Meetings ; Pharmacokinetics ; Mathematical models ; Toxicity ; Epidemiology ; Risk assessment ; Toxic substances ; Dose-response relationships ; Safe Drinking Water Act of 1974
Library Call Number Additional Info Location Last
NTIS  PB89-203319 Some EPA libraries have a fiche copy filed under the call number shown. 07/26/2022
Collation 497p
Contents: Risk assessment: historical perspectives; Tissue dosimetry in risk assessment; Modeling: an introduction; Physiologically based pharmacokinetic modeling; Allometry: body size constraints in animal design; Prediction of in vivo parameters of drug metabolism and distribution from in vitro studies; Dose, species, and route extrapolation; Uncertainty in pharmacokinetic models using SIMUSOLV; Interspecies and dose-route extrapolations; Carcinogen DNA-adducts as a measure of biological dose for risk analysis of carcinogenic data; Resources available for simulation in toxicology; Route-to-route extrapolation of dichloromethane exposure using a physiological pharmacokinetic model; Sensitivity analysis in pharmacokinetic modeling; Mutation accumulation: chronic cytotoxicant exposure; Model for ethylene chloride and its application in risk assessment; Mathematical modeling of ozone absorption in the lower respiratory tract; Development of a physiologically based pharmacokinetic model for multiday inhalation of carbon tetrachloride; The delivered/administered dose relationship and its impact on formaldehyde risk estimates; Pharmacokinetic simulation in risk assessment; Hazard assessment: ozone; Role of pharmacokinetic modeling in risk assessment; Development of multispecies, multiroute pharmacokinetic models for methylene chloride and 1,1,1-trichloroethane (methyl chloroform); Methotrexate: pharmacokinetics and assessment of toxicity; Prospective predictions and validations in anticancer therapy; The application of pharmacokinetic data in carcinogenic risk assessment.